LUMOS PHARMA INC. - C

Lumos Pharma to Participate in Upcoming Investor Conferences

10 Nov 2021 17:06:38 By Nasdaq GlobeNewswire

Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates

03 Nov 2021 16:01:01 By Nasdaq GlobeNewswire

Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

21 Oct 2021 16:05:01 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in September Investor Conferences

02 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

05 Aug 2021 08:00:02 By Nasdaq GlobeNewswire

Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer

03 Aug 2021 08:00:01 By Nasdaq GlobeNewswire

Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President

02 Aug 2021 08:00:01 By Nasdaq GlobeNewswire

Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board

26 Jul 2021 16:18:40 By Nasdaq GlobeNewswire

Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021

22 Jul 2021 08:00:04 By Nasdaq GlobeNewswire

Lumos Pharma Announces Clinical Updates

20 Jul 2021 16:01:00 By Nasdaq GlobeNewswire

Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment

28 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference

19 May 2021 09:00:02 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit

13 May 2021 09:00:01 By Nasdaq GlobeNewswire

Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

05 May 2021 16:01:00 By Nasdaq GlobeNewswire

Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021

28 Apr 2021 09:00:00 By Nasdaq GlobeNewswire

Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar

27 Apr 2021 08:00:01 By Nasdaq GlobeNewswire

Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession

20 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency

14 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency

20 Mar 2021 11:00:00 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in March 2021 Investor Conferences

11 Mar 2021 16:05:00 By Nasdaq GlobeNewswire